Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Citi
Express Scripts
Fish and Richardson
Merck
Deloitte
US Army
Argus Health
US Department of Justice

Generated: June 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020386

« Back to Dashboard

NDA 020386 describes COZAAR, which is a drug marketed by Merck Sharp Dohme and is included in one NDA. It is available from five suppliers. Additional details are available on the COZAAR profile page.

The generic ingredient in COZAAR is losartan potassium. There are thirty-seven drug master file entries for this compound. Sixty-seven suppliers are listed for this compound. Additional details are available on the losartan potassium profile page.
Summary for 020386
Tradename:COZAAR
Applicant:Merck Sharp Dohme
Ingredient:losartan potassium
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 020386
Medical Subject Heading (MeSH) Categories for 020386
Suppliers and Packaging for NDA: 020386
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
COZAAR losartan potassium TABLET;ORAL 020386 NDA Merck Sharp & Dohme Corp. 0006-0951 N 0006-0951-54
COZAAR losartan potassium TABLET;ORAL 020386 NDA Merck Sharp & Dohme Corp. 0006-0952 N 0006-0952-31

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength25MG
Approval Date:Apr 14, 1995TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength50MG
Approval Date:Apr 14, 1995TE:RLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength100MG
Approval Date:Oct 13, 1998TE:ABRLD:Yes

Expired US Patents for NDA 020386

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme COZAAR losartan potassium TABLET;ORAL 020386-001 Apr 14, 1995 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme COZAAR losartan potassium TABLET;ORAL 020386-003 Oct 13, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme COZAAR losartan potassium TABLET;ORAL 020386-002 Apr 14, 1995 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme COZAAR losartan potassium TABLET;ORAL 020386-002 Apr 14, 1995 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Daiichi Sankyo
Federal Trade Commission
Chinese Patent Office
Julphar
Queensland Health
Cipla
Cerilliant
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.